Verinurad + Febuxostat + Dapagliflozin
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Asymptomatic Hyperuricemia
Conditions
Asymptomatic Hyperuricemia
Trial Timeline
Oct 25, 2017 → Jul 19, 2018
NCT ID
NCT03316131About Verinurad + Febuxostat + Dapagliflozin
Verinurad + Febuxostat + Dapagliflozin is a phase 2 stage product being developed by AstraZeneca for Asymptomatic Hyperuricemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03316131. Target conditions include Asymptomatic Hyperuricemia.
What happened to similar drugs?
0 of 1 similar drugs in Asymptomatic Hyperuricemia were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03316131 | Phase 2 | Completed |
Competing Products
2 competing products in Asymptomatic Hyperuricemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RDEA3170 + Febuxostat + Benzbromarone | AstraZeneca | Phase 1/2 | 32 |
| Azithromycin plus chloroquine | Pfizer | Phase 3 | 32 |